Petrovich Z, Block J, Kuisk H, Mackintosh R, Casciato D, Jose L, Barton R
Cancer. 1981 May 1;47(9):2259-64. doi: 10.1002/1097-0142(19810501)47:9<2259::aid-cncr2820470926>3.0.co;2-q.
Between 1975 and 1978, 23 patients with Stage IV, unresectable, squamous cell carcinoma of the head and neck were randomized to receive radiotherapy (RT, 11 patients), or radiotherapy-chemotherapy (RT & CT, 12 patients). The response rate for the 12 RT & CT patients was four complete remissions (CR) and four partial remissions (PR); the 11 RT patients had one CR and three PR. The presence of a responses (CR or PR) significantly enhanced the median survival (14 vs. 5 months; P = 0.005). The duration of objectives remission was longer among the RT & CT patients when compared with RT patients (6 vs. 2.3 months, P = 0.18). The median survival of the RT & CT group was 12 months compared with 5.6 months for the RT group (P = 0.13). One RT & CT patient remains alive with disease at 44 months, one RT patient remains alive without disease at 30 months. The present chemotherapy regimen did not modify the pattern of failure and only marginally increased patient survival. It did, however, increase the response rate. The authors plan to reactivate the trial with modification in the induction chemotherapy and the addition of postradiation maintenance CT consisting of sequential bleomycin and cis-platinum.
1975年至1978年间，23例IV期不可切除的头颈部鳞状细胞癌患者被随机分为两组，一组接受放疗（RT，11例患者），另一组接受放疗联合化疗（RT & CT，12例患者）。12例接受RT & CT治疗的患者中，有4例完全缓解（CR），4例部分缓解（PR）；11例接受RT治疗的患者中有1例CR和3例PR。出现缓解（CR或PR）显著提高了中位生存期（14个月对5个月；P = 0.005）。与RT患者相比，RT & CT患者的客观缓解持续时间更长（6个月对2.3个月，P = 0.18）。RT & CT组的中位生存期为12个月，而RT组为5.6个月（P = 0.13）。1例接受RT & CT治疗的患者在44个月时仍带瘤存活，1例接受RT治疗的患者在30个月时无病存活。目前的化疗方案并未改变失败模式，仅略微提高了患者生存率。然而，它确实提高了缓解率。作者计划对诱导化疗进行修改并重新启动试验，并增加由序贯博来霉素和顺铂组成的放疗后维持化疗。
